Doctor of Osteopathy Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Palak Moondra

Geriatric Medicine New Brunswick, NJ Doctor of Osteopathy

NPI 1124267091 CMS profile 278234

254 Easton Ave, New Brunswick, NJ 08901

Open in the dashboard

General payments

$1,147

17 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Palak Moondra of New Brunswick, NJ is reported in the CMS Open Payments database as having received $1,147 across 17 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 77th percentile of Geriatric Medicine profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

6 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $322 5
2024 General $434 4
2023 General $214 2
2021 General $12 1
2020 General $41 3
2019 General $123 2

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Palak Moondra
  • Geriatric Medicine median
  • Middle half of Geriatric Medicine
  • National median

In program year 2025, general payments to Palak Moondra were reported at $322. Among 1,028 Geriatric Medicine profiles paid that year, the median was $123 and the middle half received between $35 and $408.

Show as a table
Year Palak Moondra Geriatric Medicine median Middle half National median
2019 $123 $122 $40–$435 $163
2020 $41 $98 $25–$349 $114
2021 $12 $125 $34–$441 $132
2022 $0 $124 $36–$408 $149
2023 $214 $121 $41–$383 $160
2024 $434 $134 $41–$435 $164
2025 $322 $123 $35–$408 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Medtronic, Inc. $158 2 payments
  2. Abbott Laboratories $156 1 payment
  3. Boston Scientific Corporation $149 1 payment
  4. Genzyme Corporation $145 1 payment
  5. Abiomed $120 1 payment
  6. Edwards Lifesciences Corporation $111 1 payment
  7. Kestra Medical Technology Services, Inc. $70 1 payment
  8. Intuity Medical Inc $69 1 payment
  9. CVRx, Inc. $53 1 payment
  10. Sanofi-Aventis U.S. LLC $50 2 payments
  11. Other $65 5 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Food and Beverage $1,147 17 payments
Products named General payments · program years 2019–2025
  1. INTELLIS ADAPTIVESTIM $158 2 payments
  2. FreeStyle Libre 3 $156 1 payment
  3. WATCHMAN FLX $149 1 payment
  4. DUPIXENT $145 1 payment
  5. Impella $120 1 payment
  6. Edwards SAPIEN 3 Transcatheter Heart Valve $111 1 payment
  7. Assure WCD $70 1 payment
  8. Pogo Automatic Blood Glucose Monitoring System $69 1 payment
  9. Barostim Neo System $53 1 payment
  10. TZIELD $50 2 payments
  11. Other $104 8 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 116 drugs

Part D claims

5,821

Median for Critical Care (Intensivists): 406

Drug cost

$415,559

Median for Critical Care (Intensivists): $197,260

Branded share of claims

16.8%

Median for Critical Care (Intensivists): 69%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Eliquis Apixaban Brand 233 $80,939
Januvia Sitagliptin Phosphate Brand 64 $41,359
Trokendi Xr Topiramate Brand 22 $32,811
Jardiance Empagliflozin Brand 32 $29,624
Farxiga Dapagliflozin Propanediol Brand 27 $22,462
Briviact Brivaracetam Brand 25 $17,397
Myrbetriq Mirabegron Brand 18 $13,226
Xarelto Rivaroxaban Brand 26 $11,962
Trulicity Dulaglutide Brand 12 $10,373
Entresto Sacubitril/Valsartan Brand 19 $7,110

The 10 drugs with the highest cost, of 116 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 1,531 Part D prescribers listed as Critical Care (Intensivists); they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 29 billing codes

Paid by Medicare

$73,328

Medicare's payments for the services billed

Medicare patients

206

Average age 81

Services billed

1,035

150 women, 56 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Arthritis 55%
Diabetes 35%
Chronic kidney disease 35%
Ischemic heart disease 31%
Atrial fibrillation 28%
Depression 28%
Heart failure 27%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Records

17 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Geriatric Medicine in New Jersey

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record